A serum-resistant polyamidoamine-based polypeptide dendrimer for gene transfection.
A serum tolerant polycation gene vector, G(2) PAMAM-PGlu-G(1) PAMAMs (ALA), was designed, synthesized, characterized and evaluated. A honeycomb-like molecular structure model for mechanistic explanation of ALA was postulated and discussed. Designed as a star-shaped polyamidoamine (PAMAM)-based polypeptide dendrimer through peptide bond linkages, ALA was with non-toxic low generation G(2) PAMAM (G(2)) as its central core, polyglutamate (PGlu)s as its star-shaped backbone branches and G(1) PAMAM (G(1))s as its branch grafts and peripheral terminals. IR, (1)H NMR demonstrated its successful combination. As a gene carrier, ALA exhibited good DNA binding and condensation capacity with particle size (approximately 87 nm for N/P 40, approximately 170 nm for N/P 30) and ζ-potential (approximately 16 mV for N/P 30-40), negligible cytotoxicity, exciting serum tolerant capacity and significant serum-promoted (serum-containing 56.6%>serum-free 32.7%), cell line dependent (Hek 293 > Bel 7402 > Hela), incubation period dependent (38 h > 18 h > 12 h > 9 h > 4 h > 2 h > 1 h) and sustained (peak transfection appeared at 30 h incubation) transfection efficiency. The presence of serum had not only no inhibition on, but also prominent promotion to, the transfection activity of ALA. All above features differentiated ALA clearly from most other serum-inhibitive nonviral gene carriers, and proved ALA the promising and challenging potential efficient gene vector for practical clinical application.
Wu
H M
HM
School of Pharmaceutical Sciences and the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. 911960923@qq.com
Pan
S R
SR
Chen
M W
MW
Wu
Y
Y
Wang
C
C
Wen
Y T
YT
Zeng
X
X
Wu
C B
CB
D002460:Cell Line; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D050091:Dendrimers / Q000008:administration & dosage / Q000009:adverse effects / Q000138:chemical synthesis / Q000737:chemistry*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000009:adverse effects / Q000138:chemical synthesis / Q000737:chemistry; D006367:HeLa Cells; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D010455:Peptides / Q000737:chemistry*; D011094:Polyethyleneimine / Q000737:chemistry*; D017550:Spectroscopy, Fourier Transform Infrared; D014162:Transfection / Q000379:methods*
D050091:Dendrimers; D010455:Peptides; D011094:Polyethyleneimine